|Articles|April 6, 2022
Celerion Announces Investment in ADME Suite of Services
Expansion of services to meet increasing demand from industry.
Advertisement
Celerion has announced that it has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services to meet continuously increasing demand to conduct these studies. This investment includes expanding laboratory space, adding new capabilities as well as a dedicated customer service team.
Read more about Celerion's new investment
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
2
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
3
FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results
4
ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
